Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

ANRO vs ATYR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ATYR Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 1–3 Matrix Metrics)

ATYR Overall Winner 6-Pillar Tally: ANRO 2 – 2 ATYR (2 Tie) Matrix Metrics: ANRO 3 – 1 ATYR

As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) is the stronger overall head-to-head candidate over Alto Neuroscience Inc. (ANRO) in the Tradestie Institutional Equity Comparison Engine, winning 1–3 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). ANRO carries a Unified Composite Score of 34.3/100 (SELL) at $25.11 (N/M Forward P/E, 0.0% operating margin), whereas ATYR carries 34.3/100 (SELL) at $4.96 (N/M Forward P/E, 0.0% operating margin).

  • Defensive Composite Rating Caution: Although ATYR compares more favorably head-to-head, both ANRO (34.3/100 SELL) and ATYR (34.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: ANRO is currently in a Breakdown options structure phase (RSI 48.0); meanwhile ATYR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 57.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ANRO vs ATYR
ANRO NYSE
Alto Neuroscience Inc.
Pharmaceutical Preparations
$25.11
-7.41% 1D
Market Cap $1.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.02β · 93% Vol
Unified Composite Score
34.3 / 100 SELL
Tech 15.0 Fund 38.0 Flow 64.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 48.0 · SMA20: $24.87 · SMA50: $25.98
ATYR NASDAQ Head-to-Head Winner
aTyr Pharma, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$4.96
-5.34% 1D
Market Cap $15.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -9.67β · 13806% Vol
Unified Composite Score
34.3 / 100 SELL
Tech 50.0 Fund 36.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (391.4% over 20 days), RSI 58
RSI-14: 57.6 · SMA20: $4.36 · SMA50: $1.92

6-Pillar Scorecard Institutional Category Breakdown (ANRO 2 – 2 ATYR)

Columns: Metric · ANRO · ATYR
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale ANRO
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $1.2B $15.6M
3. Profitability & Quality ANRO
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -46.7% -93.7%
4. Balance Sheet & Cash Flow ATYR
Cash Generation (TTM) -$80M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $301M Net Cash $4.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ATYR
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 79.4% (8th %ile) 154.5% (36th %ile)
Put/Call OI Skew 0.04x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ANRO (3) vs ATYR (1)
Institutional Metric ANRO ATYR Criterion Row Edge
Market Capitalization
Scale
$1.2B $15.6M Larger Scale ANRO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-46.7% -93.7% Higher ROE ANRO
52-Week Range Position
Momentum
54% ($11–$37) 62% ($0–$8) Stronger Trend ATYR
Beta / 30D Volatility
Risk Regime
2.02β · 93% Vol -9.67β · 13806% Vol Lower Realized Risk ANRO
Unified Institutional Score
Composite Signal
34.3 / 100 (SELL) 34.3 / 100 (SELL) Higher Composite Tie
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$80M ($301M Net Cash) N/A ($4.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ATYR +2778.72 pp
ANRO: +10.04% · ATYR: +2788.76%
3M Horizon ATYR +858.96 pp
ANRO: -28.03% · ATYR: +830.93%
6M Horizon ATYR +904.13 pp
ANRO: +22.79% · ATYR: +926.92%
1Y Horizon ATYR +451.35 pp
ANRO: +107.35% · ATYR: +558.7%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANRO vs ATYR. Trailing 12-month operating profitability (ANRO 0.0% vs ATYR 0.0%) and valuation multiples (ANRO N/M vs ATYR N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ANRO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-46.7% · N/M
ATYR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-93.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ANRO BREAKDOWN
58d in phase · OBV ACCUMULATION
Current IV 79.4%
IV Percentile 8th %ile
Put/Call OI Skew 0.04x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ANRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ATYR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 154.5%
IV Percentile 36th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ATYR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ANRO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ATYR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ANRO vs ATYR Key Questions & Quantitative Answers

As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) is the stronger overall head-to-head candidate over Alto Neuroscience Inc. (ANRO) in the Tradestie Institutional Equity Comparison Engine, winning 1–3 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). ANRO carries a Unified Composite Score of 34.3/100 (SELL) at $25.11 (N/M Forward P/E, 0.0% operating margin), whereas ATYR carries 34.3/100 (SELL) at $4.96 (N/M Forward P/E, 0.0% operating margin). Defensive Composite Rating Caution: Although ATYR compares more favorably head-to-head, both ANRO (34.3/100 SELL) and ATYR (34.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: ANRO is currently in a Breakdown options structure phase (RSI 48.0); meanwhile ATYR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 57.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ANRO leads the Growth & Scale pillar: ANRO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ATYR at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ANRO generates N/A in USD-normalized revenue versus N/A for ATYR. In operating R&D and SG&A reinvestment, ANRO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ATYR.

ANRO and ATYR trade at balanced relative valuation multiples. ANRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ATYR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ANRO (-46.7% ROE) versus ATYR (-93.7% ROE) capital efficiency.

In options market volatility and institutional positioning, ANRO carries 79.4% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.04x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (2.02β · 93% Vol realized risk). By comparison, ATYR carries 154.5% implied volatility (36th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-9.67β · 13806% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.